A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With MVA-Mosaic OR Ad26.Mos4.HIV Plus a Combination of Mosaic and Clade C gp140 Protein in HIV-1 Infected Adults on Suppressive ART

Trial Profile

A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With MVA-Mosaic OR Ad26.Mos4.HIV Plus a Combination of Mosaic and Clade C gp140 Protein in HIV-1 Infected Adults on Suppressive ART

Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 May 2018

At a glance

  • Drugs Ad26 Mos4 HIV (Primary) ; MVA-Mosaic-HIV-vaccine-Janssen-Vaccines-and-Prevention (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Sponsors Janssen Vaccines and Prevention B.V
  • Most Recent Events

    • 01 May 2018 Status changed from not yet recruiting to recruiting.
    • 06 Mar 2018 Planned initiation date changed from 14 Feb 2018 to 5 Mar 2018.
    • 11 Dec 2017 Planned End Date changed from 9 Mar 2020 to 12 Jun 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top